Cannabis industry officials are analyzing the potential consequences of federal marijuana rescheduling for both patients and businesses nationwide. NPR host Michel Martin recently spoke with Gillian Schauer, who serves as executive director of the Cannabis Regulators Association, about what immediate changes consumers and the industry might expect.
The conversation centered on how shifts in federal cannabis classification could reshape the landscape for medical marijuana users and the companies that serve them. Industry leaders are closely monitoring these developments as they could significantly alter how cannabis is regulated and accessed across the country.
